Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi/Regeneron Choose Access Over Price With Dupixent Launch

Executive Summary

The FDA approved the IL-4/IL-13 inhibitor March 28 in a win for Sanofi and Regeneron. The companies set the biologic's price at $37,000 per year, which is lower than many biologics on the market for psoriasis.

You may also be interested in...



Pfizer's Oral Abroctinib Bests Injectable Dupixent In Atopic Dermatitis Trial

Only top-line data were released by Pfizer, and the safety of abrocitinib, like other JAK inhibitors, could remain an issue.

Sanofi CEO Hudson Delivers An Ambitious Turnaround Agenda

CEO Paul Hudson came to Sanofi's capital markets day with big news and key messages for investors about the company's future business model. 

Dupixent Gets Room To Grow With New Indication In Chronic Rhinosinusitis

The new indication represents the third one for Sanofi/Regeneron's IL-4/IL-13 inhibitor, after atopic dermatitis and moderate to severe asthma.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC098471

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel